GlassScriptPhysician profile
Rollin George
NPI 1386023059
$4,979.26
in general payments reported to CMS, 2019-2025
29 companies · $977 in 2025
The $977 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,372 · 2020: $215 · 2021: $117 · 2022: $544 · 2023: $761 · 2024: $993 · 2025: $977.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,717 · Education: $13.76.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,716.77 |
| Education | $13.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $841.59 | 2019-2025 | |
| Boston Scientific Corporation | $496.82 | 2022-2025 | Orise, Wallflex Duodenal, Overstitch Endoscopic Suturing System |
| Takeda Pharmaceuticals U.S.A., INC. | $326.97 | 2019-2024 | Entyvio, Eohilia, Gattex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $316.03 | 2019-2024 | Xifaxan |
| Conmed Corporation | $272.14 | 2023-2025 | Conmed Hemostasis, Conmed Generators |
| Janssen Scientific Affairs, LLC | $231.96 | 2019 | |
| Gi Supply, INC. | $224.76 | 2019 | |
| Phathom Pharmaceuticals, INC. | $215.75 | 2023-2025 | Voquezna |
| Medtronic, INC. | $215.56 | 2021-2025 | Endoflip |
| Johnson & Johnson Health Care Systems INC. | $211.67 | 2023-2024 | Stelara, Darzalex |
| Steris Corporation | $205.56 | 2022 | |
| Janssen Biotech, INC. | $170.05 | 2023-2025 | Stelara, Tremfya |
| Qol Medical, LLC | $141.08 | 2020-2023 | Sucraid |
| Fujifilm Healthcare Americas Corporation | $140.55 | 2025 | |
| Pentax of America, INC. | $137.72 | 2019 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merit Medical Systems INC | $120.06 | 2025 | Esophyx |
| Lilly USA, LLC | $114.24 | 2024 | Omvoh |
| Novo Nordisk INC | $110.23 | 2022 | |
| Madrigal Pharmaceuticals | $97.91 | 2025 | Rezdiffra |
| Merck Sharp & Dohme LLC | $78.35 | 2023-2024 | Dificid |
| Regeneron Healthcare Solutions, INC. | $50.26 | 2025 | Dupixent |
| Endogastric Solutions, INC | $50.04 | 2022 | |
| Apollo Endosurgery US INC | $49.41 | 2021 | |
| Shionogi INC | $45.30 | 2019 | |
| Stryker Corporation | $32.16 | 2022 | |
| Shire North American Group INC | $31.43 | 2019 | |
| Genzyme Corporation | $19.55 | 2024 | |
| Otsuka America Pharmaceutical, INC. | $17.14 | 2019 | |
| Erbe USA INC | $14.97 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rollin George listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.